BEIJING – China will kickstart a phase III trial Feb. 3 to determine whether patients with 2019-nCoV can be treated with Gilead Sciences Inc. ’s NUC inhibitor, remdesivir , which was originally developed for Ebola, four days after a U.S. patient was said to have recovered by using the […]
